A New Flu Shot Is Here, Powered by mRNA Tech!
Good news for folks aged 50 and up! The FDA has just given a nod to a new flu vaccine called mFlusiva, which uses the same cutting-edge mRNA technology that helped us through the Covid-19 pandemic. This could mean a more adaptable and quick
It's always a good idea to stay ahead of the flu, especially as we get a little older. That's why we're excited to share some news about a brand-new flu vaccine. The Food and Drug Administration (FDA) has approved mFlusiva, a new flu shot from Moderna, specifically for adults aged 50 and above. What makes this special is that it's the very first flu vaccine to use the mRNA technology, which you might recognize from the Covid-19 vaccines.
You might be wondering, why does this matter? Well, flu season comes around every year, and the virus is constantly changing. Having a vaccine that can be made more quickly, thanks to this mRNA platform, is a big step forward. Experts believe this could be a game-changer if we ever face a flu strain that mutates unexpectedly and requires a fast turnaround for new vaccine doses.
What to Expect from mFlusiva
For those between 50 and 64, mFlusiva received full FDA approval after a study involving 40,000 people showed it reduced flu cases by about 27% compared to another common flu vaccine. If you're 65 or older, the approval is 'accelerated,' meaning it's based on strong immune responses seen in a smaller study. Moderna is continuing to gather more data for this age group.
As for side effects, they're generally similar to what you might experience with other flu shots – things like a sore arm, a bit of a fever, headache, or feeling tired and achy. These are usually temporary and a sign your body is building protection.
A Smooth Road Ahead for Flu Season?
While there are already many great flu vaccine options available, especially for older adults, the flu still causes thousands of deaths each year. This new mRNA-based vaccine adds another important tool to our toolbox. It's also interesting to note that this vaccine faced some public debate earlier in the year, but ultimately, an independent panel of experts unanimously recommended its approval.
So, as flu season approaches, keep an eye out for mFlusiva at select retailers. It's another positive step in keeping ourselves and our communities healthy and well-protected.
Written by Limmizen Newsroom
Originally reported by The Guardian. This piece is a Limmizen rewrite in our own voice.